2 more cases of measles confirmed in metro Atlanta
The two cases were unvaccinated family members of the case confirmed in January.
DPH contacted some people who may have been exposed through contact with the people with measles.
They have been given a vaccine or antibodies to help reduce the risk of developing measles.
Currently, no secondary cases have been reported outside of the family.
The MMR (measles, mumps, rubella) vaccine can prevent measles and rubella.
The Atlanta-based Centers for Disease Control and Prevention (CDC) recommends children receive their first dose of MMR vaccine between 12 and 15 months of age and a second dose between 4 and 6 years old.
Over 95% of the people who receive a single dose of MMR will develop immunity to all three viruses.
That immunity is typically boosted to 98% with a second dose.
For more information about measles, visit https://dph.georgia.gov/epidemiology/acute-disease-epidemiology/vaccine-preventable-diseases/measles.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
TRENDING STORIES:
Suspect in custody after shooting, killing police officer just 'serving the citizens of Roswell'
Metro police departments offer condolences to 'hero' officer shot, killed in line of duty
4 men show up injured at Grady Hospital following shooting in Southeast Atlanta
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Patientory's AI-Enterprise Analytics Dashboard Now Available on Oracle Healthcare Marketplace
Patientory's Enterprise Analytics Dashboard is now integrated with Oracle Health technologies to support proactive care, clinical trial recruitment, and strategic decision-making. ATLANTA, Aug. 19, 2025 /PRNewswire/ -- Patientory, Inc., a leading provider of Web3-enabled digital health solutions and an Oracle partner, today announced that its AI-Enterprise Analytics Dashboard is now available on Oracle Healthcare Marketplace and can be integrated with Oracle Health EHR systems. Oracle Healthcare Marketplace is a centralized repository of healthcare applications offered by Oracle and Oracle partners. The Enterprise Analytics Dashboard enables high-level business benefits by providing healthcare organizations with near real-time, AI-powered insights on population health trends, patient adherence, and clinical trial readiness. By running on Oracle Cloud Infrastructure (OCI) and integrating with Oracle Health technologies, the solution empowers providers, payers, and research sponsors to drive value-based care, enhance patient engagement, and improve clinical trial diversity and speed. Oracle Healthcare Marketplace is a one-stop shop for Oracle customers seeking trusted healthcare applications offering unique clinical and business solutions, including ones that extend Oracle Health and Oracle Cloud Applications. "Making our Enterprise Analytics Dashboard available on the Oracle Healthcare Marketplace gives hospitals, research institutions, and health plans the tools to better understand their populations and respond faster," said Chrissa McFarlane, CEO, Patientory, Inc. "Patientory's participation in Oracle Healthcare Marketplace further extends our commitment to the Oracle community and enables customers to easily reap the benefits of our Enterprise Analytics Dashboard. We look forward to leveraging the power of the Oracle Cloud and Oracle Health technologies to help us achieve our business goals." This advanced analytics tool works in conjunction with the Patientory Digital Health Wallet, enabling patient engagement and chronic disease management in alignment with recent White House initiatives focused on digital health equity and chronic care innovation. Patientory will be showcasing the Enterprise Analytics Dashboard at the Oracle Health Summit, September 9–11, 2025, demonstrating how the platform leverages blockchain and AI to create actionable insights for health systems and research institutions. About Patientory, is a pioneer in Web3 digital health solutions, empowering individuals and healthcare organizations with blockchain-based tools to manage health data, reduce costs, and improve outcomes. Our platform bridges the gap between patients, providers, and researchers—enabling real-time analytics, chronic disease management, and decentralized clinical trial more: About Oracle's Partner ProgramOracle's partner program helps Oracle and its partners drive joint customer success and business momentum. The newly enhanced program provides partners with choice and flexibility, offering several program pathways and a robust range of foundational benefits spanning training and enablement, go-to-market collaboration, technical accelerators, and success support. To learn more, visit Trademarks Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing. COMPANY CONTACT INFOsupport@ View original content to download multimedia: SOURCE Patientory Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Boston Globe
an hour ago
- Boston Globe
US pediatricians' new COVID-19 shot recommendations differ from CDC advice
'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. Advertisement That differs from guidance established under US Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. Advertisement The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, US Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. Advertisement But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient.
Yahoo
an hour ago
- Yahoo
Germany's Merck receives approval for cancer drug after takeover deal
The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the Darmstadt-based firm said on Monday. The drug is approved as a therapy for the treatment of rare soft tissue tumours in adults. Ogsiveo is the first and only therapy approved in the EU for the treatment of so-called desmoid tumours. The drug was developed by US biopharmaceutical company Springworks Therapeutics, which Merck only acquired in July for around €3 billion ($3.5 billion), the largest acquisition in Merck's pharmaceuticals business in almost 20 years. Desmoid tumours are rare, locally aggressive tumours that grow in the connective tissue of the body. According to the figures, around 1,300 to 2,300 new cases are diagnosed in the EU every year. The tumours can lead to severe pain, restricted mobility and severe, persistent fatigue and are difficult to treat. Ogsiveo is already on the market in the United States. Merck acquired Springworks in the expectation that the company would also receive marketing authorization in the EU. Merck chief executive Belén Garijo hopes that Ogsiveo will become a blockbuster drug and generate annual sales of at least $1 billion for the group, she told dpa in July. Merck's pharmaceutical division - with drugs for cancer, infertility and multiple sclerosis - has seen solid growth recently. However, the company is under pressure to bring new drugs onto the market. Several promising drugs have failed in clinical trials. Merck recently had to lower its sales targets in several divisions following a weak second quarter. Merck shares have recently performed weakly. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
